Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
Development of small molecular kinase inhibitors has recently been the central focus in drug discovery. And type II kinase inhibitors that target inactive conformation of kinases have attracted particular attention since their potency and selectivity are thought to be easier to achieve compared with their counterpart type I inhibitors that target active conformation of kinases. Although mechanisms underlying the interactions between type II inhibitors and their targeting kinases have been widely studied, there are still some challenging problems, for example, how type II inhibitors associate with or dissociate from their targeting kinases. In this investigation, steered molecular dynamics simulations have been carried out to explore the possible dissociation pathways of typical type II inhibitor imatinib from its targeting protein kinases c-Kit and Abl. The simulation results indicate that the most favorable pathway for imatinib dissociation corresponds to the ATP-channel rather than the relatively wider allosteric-pocket-channel, which is mainly due to the different van der Waals interaction that the ligand suffers during dissociation. Nevertheless, the direct reason comes from the fact that the residues composing the ATP-channel are more flexible than that forming the allosteric-pocket-channel. The present investigation suggests that a bulky hydrophobic head is unfavorable, but a large polar tail is allowed for a potent type II inhibitor. The information obtained here can be used to direct the discovery of type II kinase inhibitors.
Yang
Li-Jun
LJ
State Key Laboratory of Biotherapy and Cancer Center, West China Medical School, Sichuan University, West China Hospital, Chengdu, People's Republic of China.
Zou
Jun
J
Xie
Huan-Zhang
HZ
Li
Lin-Li
LL
Wei
Yu-Quan
YQ
Yang
Sheng-Yong
SY
D000255:Adenosine Triphosphate / Q000378:metabolism; D001549:Benzamides; D000068877:Imatinib Mesylate; D007473:Ion Channels / Q000378:metabolism; D008024:Ligands; D008958:Models, Molecular; D056004:Molecular Dynamics Simulation; D010879:Piperazines / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D017433:Protein Structure, Secondary; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D019009:Proto-Oncogene Proteins c-kit / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D011743:Pyrimidines / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D013816:Thermodynamics
D001549:Benzamides; D007473:Ion Channels; D008024:Ligands; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D000255:Adenosine Triphosphate; D019009:Proto-Oncogene Proteins c-kit; D016315:Proto-Oncogene Proteins c-abl